MetaVia Inc. (NASDAQ:MTVA – Get Free Report)’s share price dropped 1.9% during trading on Thursday. The company traded as low as $1.52 and last traded at $1.54. 46,623 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 87,016 shares. The stock had previously closed at $1.57.
Analyst Ratings Changes
A number of brokerages have commented on MTVA. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. Finally, HC Wainwright restated a “buy” rating on shares of MetaVia in a research note on Friday, July 10th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.
View Our Latest Analysis on MetaVia
MetaVia Price Performance
MetaVia (NASDAQ:MTVA – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). Research analysts anticipate that MetaVia Inc. will post -2.79 EPS for the current year.
MetaVia Company Profile
MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for obesity, metabolic disorders and related diseases. The company’s programs are designed to address conditions such as obesity-associated liver disease and other complications of metabolic dysfunction.
MetaVia’s lead product candidate is pemvidutide, an investigational once-weekly dual GLP-1 and glucagon receptor agonist. The company is evaluating pemvidutide for chronic weight management and metabolic dysfunction-associated steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis or MASH.
Featured Articles
- Five stocks we like better than MetaVia
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
- Conagra’s Turnaround Is Starting to Show Up in the Numbers
- MarketBeat Week in Review – 09/28 – 10/02
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
